EU/3/16/1774

Table of contents

About

On 18 November 2016, orphan designation (EU/3/16/1774) was granted by the European Commission to Fate Therapeutics Ltd, United Kingdom, for allogeneic peripheral blood mononuclear cells incubated ex-vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone (also known as ProTmune) for treatment in haematopoietic stem cell transplantation.

The sponsorship was transferred to Fate Therapeutics B.V., the Neterlands, in May 2019.

Key facts

Active substance
allogeneic peripheral blood mononuclear cells incubated ex-vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone
Disease / condition
Treatment in haematopoietic stem cell transplantation
Date of first decision
18/11/2016
Outcome
Positive
EU designation number
EU/3/16/1774

Sponsor's contact details

Fate Therapeutics B.V.
Kingsfordweg 151
1043 GR Amsterdam
Noord-Holland
The Netherlands
E-mail: info@fatetherapeutics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating